BioCentury | Oct 4, 2019
Clinical News

Arbutus scuttles lead HBV capsid inhibitor program

...emergence of a safety signal in two healthy volunteers in a Phase I study of AB-506... treat HBV. Arbutus Biopharma Corp. (NASDAQ:ABUS) said late Thursday it has discontinued development of AB-506...
...HBsAg expression and host immune response. It had planned 2H20 starts for clinical trials of AB-506...
BioCentury | Aug 12, 2017
Product Development

HBV test kitchen have an inappropriately assembled capsid, you can retard viral replication,” said Murray. Follow-on candidate AB-506...
Items per page:
1 - 2 of 2